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Pulmonary arterial hypertension (PAH) is a 
devastating and life-threatening condition with 
high morbidity and mortality that often affects 
the young (Humbert, 2008). The disease is charac-
terized by a progressive pulmonary vasculop-
athy that leads to an elevation in pulmonary 
artery pressure (PAP), right ventricular hyper-
trophy (RVH), and finally right ventricular 
failure (Chin et al., 2005; Hemnes and Cham-
pion, 2008; Humbert and McLaughlin, 2009). 
Pathologically, PAH is characterized by me-
dial thickening, intimal fibrosis, and, in some 
cases, plexiform lesions of pulmonary arteri-
oles. Multiple cell types are involved in this 
process, and evidence supports a central role 
for endothelial dysfunction followed by fi-
broblast and smooth muscle cell (SMC) prolif-
eration and migration (Morrell et al., 2009). 
Current therapies are effective in relieving 
symptoms but provide only modest improve-
ments in overall survival and do little to address 
the underlying cellular proliferation in PAH.
Our understanding of the molecular and 
cellular mechanisms involved in the pathogen-
esis of PAH has improved significantly over the 
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Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by the 
progressive narrowing and occlusion of small pulmonary arteries. Current therapies fail to 
fully reverse this vascular remodeling. Identifying key pathways in disease pathogenesis is 
therefore required for the development of new-targeted therapeutics. We have previously 
reported tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) immunoreactivity 
within pulmonary vascular lesions from patients with idiopathic PAH and animal models. 
Because TRAIL can induce both endothelial cell apoptosis and smooth muscle cell prolifera-
tion in the systemic circulation, we hypothesized that TRAIL is an important mediator in the 
pathogenesis of PAH. We demonstrate for the first time that TRAIL is a potent stimulus for 
pulmonary vascular remodeling in human cells and rodent models. Furthermore, antibody 
blockade or genetic deletion of TRAIL prevents the development of PAH in three indepen-
dent rodent models. Finally, anti-TRAIL antibody treatment of rodents with established PAH 
reverses pulmonary vascular remodeling by reducing proliferation and inducing apoptosis, 
improves hemodynamic indices, and significantly increases survival. These preclinical investi-
gations are the first to demonstrate the importance of TRAIL in PAH pathogenesis and 
highlight its potential as a novel therapeutic target to direct future translational therapies.
© 2012 Hameed et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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et al., 2000). We have previously demonstrated that TRAIL 
protein is associated with concentric and plexiform pulmo-
nary vascular lesions from patients with IPAH (Lawrie et al., 
2008) and from a murine model of severe PAH (Lawrie et al., 
2011). Other investigators have subsequently described pro-
proliferative effects of TRAIL on systemic VSMC (Secchiero 
et al., 2004; Kavurma et al., 2008) and propose a role in neo-
intimal formation in mice after a vascular injury (Chan et al., 
2010) in atherosclerosis (Watt et al., 2011) and coagulation 
(Simoncini et al., 2009). However, its role in the pathogenesis 
of PAH had yet to be investigated. Interestingly, local inflam-
matory signals are also thought to play an important role in 
pulmonary vascular disease, and recent work has demonstrated 
that TRAIL can mediate the expression and release of proin-
flammatory cytokines from SMC (Song et al., 2011) as well as 
tumor cells (Tang et al., 2009) via activation of NF-.
Because TRAIL protein expression is increased in pulmo-
nary vascular lesions from both human and rodent models, we 
hypothesized that TRAIL is involved in the pathogenesis of 
PAH. To test this hypothesis, we sought to determine whether 
inhibition of TRAIL would have a beneficial effect on pre-
clinical animal models and therefore represent a potential tar-
get for therapy in PAH.
We report here for the first time that expression of TRAIL 
is up-regulated in PA-SMCs isolated from patients with IPAH 
and that TRAIL is a mitogen and promigratory stimulus to 
human pulmonary artery SMCs (PASMCs) in vitro. We dem-
onstrate that TRAIL is required for the development of PAH 
in three rodent models through blockade of TRAIL, either by 
genetic deletion (mouse) or with an anti-TRAIL antibody 
(rat). In addition, giving exogenous, recombinant TRAIL to 
the ApoE//TRAIL/ mice resulted in the reestablishment 
of PAH. In intervention studies on models with established dis-
ease, TRAIL blockade significantly reduced pulmonary 
vascular remodeling and increased survival in a rat monocro-
taline (MCT) model and in a murine model of severe PAH 
resulted in regression of pulmonary vascular remodeling with 
virtual normalization of right ventricular pressures. These 
therapeutic effects were associated with a reduction in prolif-
erating cells and an increase in apoptotic cells within the distal 
pulmonary arteries and arterioles.
RESULTS
TRAIL expression is increased in PAH and induces 
proliferation and migration of PASMCs in vitro
TRAIL mRNA expression was significantly increased in 
PASMC explanted and grown in vitro from transplanted lungs 
of patients with IPAH compared with control patient cells 
(Fig. 1 A). The addition of rTRAIL to hPASMC in vitro resulted 
in a dose–response increase in both proliferation (Fig. 1 B) and 
migration (Fig. 1 C) with 30 ng/ml deemed to be the lowest 
dose with maximal effect. Because TRAIL naturally forms a 
homotrimer that binds to TRAIL receptors, we also examined 
the effect of using cross-linked TRAIL (anti-histidine antibody) 
and observed equivalent data (not depicted). We next examined 
the downstream signaling associated with rTRAIL-mediated 
past decade, particularly because of the discovery of muta-
tions in the BMPR2 (bone morphogenetic protein type 2 re-
ceptor; Lane et al., 2000). In addition, several growth factors 
such as PDGF (Schermuly et al., 2005; Perros et al., 2008), 
mitogens such as 5-Hydroxytriptamine and S100A4 (Lee et al., 
1999; Lawrie et al., 2005), and cytokines such as IL-1 and 
IL-6 (Humbert et al., 1995; Steiner et al., 2009; Lawrie et al., 
2011) have been implicated in the disease process, either in 
their own right or by interaction with the BMP signaling 
(Long et al., 2006; Hagen et al., 2007; Hansmann et al., 2008; 
Lawrie et al., 2008).
TNF-related apoptosis-inducing ligand (TRAIL; Apo2L) 
is a type II transmembrane protein whose transcripts are 
detected in a variety of human tissues, most predominantly 
in spleen, lung, and prostate (Wiley et al., 1995). They can be 
alternatively spliced to produce several different isoforms 
(Wang et al., 2011). There are four membrane TRAIL re-
ceptors, DR4 (death receptor 4, TRAIL-R1; Pan et al., 
1997b), DR5 (TRAIL-R2; MacFarlane et al., 1997; Pan 
et al., 1997b; Screaton et al., 1997; Walczak et al., 1997), 
DcR1 (Decoy Receptor 1, TRAIL-R3; Degli-Esposti et al., 
1997b; Pan et al., 1997a; LeBlanc and Ashkenazi, 2003), DcR2 
(TRAIL-R4; Degli-Esposti et al., 1997a; Marsters et al., 
1997; Pan et al., 1998), and the soluble protein OPG (os-
teoprotegerin) (Emery et al., 1998). In rodents, there is 
only one TRAIL death receptor (Wu et al., 1999). Both 
TRAIL-R1 and TRAIL-R2 contain a conserved DD (death 
domain) motif and mediate the extrinsic apoptosis pathway 
by TRAIL (Ashkenazi and Dixit, 1998). TRAIL-R3 lacks 
an intracellular domain and TRAIL-R4 has a truncated DD; 
both are therefore considered decoy receptors to antagonize 
TRAIL-induced apoptosis by competing for ligand binding 
along with OPG (Ashkenazi and Dixit, 1998; LeBlanc and 
Ashkenazi, 2003; Miyashita et al., 2004).
TRAIL has long been explored as an anti-cancer ther-
apy (Wu, 2009) as a result of its innate ability to induce 
apoptosis in a variety of transformed or tumor cells while 
leaving normal, untransformed cells unaffected (Wiley et al., 
1995; Pitti et al., 1996). Many cancer cells have subsequently 
been found to be resistant to TRAIL-induced apoptosis 
(Wu, 2009), the mechanism of which is not fully under-
stood but may be dependent on the regulation and expres-
sion of TRAIL receptors by genetic (Pai et al., 1998) and 
epigenetic changes (Hopkins-Donaldson et al., 2003) as well 
as modulation of OPG expression (Holen and Shipman, 
2006; De Toni et al., 2008).
TRAIL has also been shown to be important in the early 
resolution of inflammation (McGrath et al., 2011) and to 
have immunosuppressive and immunoregulatory functions 
that are important for lymphocyte homeostasis and the tran-
sition between innate-to-adaptive immunity (Falschlehner 
et al., 2009). Interactions between inflammation and vascular 
cells are a key aspect of vascular injury/repair and are consid-
ered to have an important role in cardiovascular disease. 
TRAIL mRNA and protein expression has previously been 
described in normal human pulmonary arteries (Gochuico 
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demonstrate significantly attenuated TRAIL-induced prolif-
eration of PASMC with antibody neutralization of TRAIL-
R3 (Fig. 1 H).
TRAIL expression in pulmonary arterioles increases  
with development of PAH in the MCT rat model
We have previously described the presence of TRAIL protein 
expression within pulmonary vascular lesions of both end-stage 
transplanted human and experimental model mouse lungs. To 
determine both the spatial and temporal expression of TRAIL in 
PAH pathogenesis, we initiated a time course of disease using the 
proliferation and migration. Addition of 30 ng/ml TRAIL re-
sulted in a significant increase in the phosphorylation of the 
extracellular regulated kinase 1/2 (Fig. 1 D), and the addition 
of the specific inhibitor PD98059 resulted in an inhibition of 
both TRAIL-mediated proliferation (Fig. 1 E) and migration 
(Fig. 1 F). Previous studies have implicated both TRAIL-R1 
and TRAIL-R3 in the proliferative response to TRAIL in 
systemic SMC (Kavurma et al., 2008). We examined the ex-
pression of all known cell surface TRAIL receptors and found 
that TRAIL-R1 and, predominantly, TRAIL-R3 was signifi-
cantly elevated in patient cells (Fig. 1 G). Furthermore, we 
Figure 1. TRAIL induces proliferation and migration of PASMCs. (A) TaqMan expression of TRAIL in explanted PASMC from patients with IPAH normalized 
using CT with 18S rRNA as the endogenous control gene. Human PA-SMCs were serum starved for 48 h before stimulation with 1–100 ng/ml of recombinant 
TRAIL or 10 ng/ml PDGF-BB. (B) Proliferation was assessed by cell counting at 72 h. (C) migration was measured at 6 h using a Boyden Chamber assay and nor-
malized relative to unstimulated cells (0.2% FCS). (D) Time course of p42/44 / ERK1/2 phosphorylation in PASMC using 30 ng/ml of TRAIL. Black lines indicate that 
intervening lanes have been spliced out. (E and F) Treatment of PASMC with the ERK1/2 inhibitor PD98059 inhibited TRAIL (30 ng/ml)-induced proliferation (E) and 
migration (F). (G) TaqMan expression of TRAIL receptors in explanted PASMC from patients with IPAH normalized using CT with 18S rRNA as the endogenous 
control gene. Human PA-SMCs were stimulated with 30 ng/ml of recombinant TRAIL or 20 ng/ml PDGF-BB with blocking antibodies for TRAIL-R1, TRAIL-R3, or an 
IgG control. (H) Proliferation of human PA-SMCs in response to 30 ng/ml of recombinant TRAIL or 20 ng/ml PDGF-BB after preincubation with IgG or neutralizing 
antibodies for TRAIL-R1, TRAIL-R3, or an IgG control. Error bars represent mean ± SEM, and all experiments were performed in triplicate. For data using patient 
material (A and G), n = 3. All remaining figures, n = 5. *, P < 0.05; **, P < 0.01; ***, P < 0.001, compared with 0.2% FCS, control, or 0 h samples.
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AT (Fig. 3 E), increased cardiac index (Fig. 3 F), reduced ePVRi 
(Fig. 3 G), and RVH (Fig. 3 H) 21 d after MCT injection. 
There was no significant difference in left ventricular hemo-
dynamics (Fig. 3, C and D). The anti-TRAIL antibody–treated 
rats also showed significant reduction in the degree of pulmo-
nary vascular remodeling as measured by media/cross-sectional 
area (Fig. 3, I and L), which was associated with a significant re-
duction in proliferation (Fig. 3, J and L) and an increase in 
apoptosis in the small pulmonary arteries and arterioles (Fig. 3, 
K and L). No increase in apoptosis of systemic vasculature tis-
sue was observed (unpublished data).
TRAIL/ mice are protected from chronic  
hypoxia-induced pulmonary hypertension (PH)
To test whether the loss of TRAIL expression would prevent 
the development of PH in a murine model, we exposed male 
TRAIL/ mice to 2 wk of chronic hypoxia (10% O2). C57BL/6 
control mice developed significant increases in RVSP (38.9 ± 
2.6 mm Hg; Fig. 4 A), mildly raised RVEDP (Fig. 4 B), signifi-
cantly reduced PA AT (Fig. 4 E) and cardiac index (Fig. 4 F), and 
significantly increased ePVRi (Fig. 5 G) compared with nor-
moxic controls (Table S3). Pulmonary vascular remodeling of the 
small arterioles comprising smooth muscle actin (SMA)–positive 
cells was also observed in hypoxia-stimulated C57BL/6 mice 
(Fig. 4, I–K). In stark contrast, there was no evidence of PH in 
either the normoxic or hypoxic TRAIL/ mice (Fig. 4, A–K). 
There was no evidence of any alterations in left ventricular 
hemodynamics between either genotype or hypoxia expo-
sure (Fig. 4, C and D).
MCT rat model of disease. Histological and immunohistochem-
istry analysis of serial lung tissue samples revealed evidence of 
pulmonary vascular remodeling from day 14, leading to progres-
sive muscularization in the small resistance pulmonary arteries 
and arterioles (<50 µm) in MCT-treated rats (Fig. 2). TRAIL 
immunoreactivity was observed in epithelial and endothelial cells 
of saline-treated animals at all time points. There was an increase 
in the medial and perivascular tissue from around day 21 in the 
MCT-treated rats that coincided with the peak of pulmonary 
vascular remodeling and hemodynamic alterations associated 
with this model.
Treatment with an anti-TRAIL antibody prevents  
the development of PAH in the MCT rat model
Because TRAIL expression increased with disease progres-
sion, we next aimed to determine whether blocking endoge-
nous TRAIL with an anti-TRAIL antibody would modulate 
the development of PAH in the MCT rat model. Rats were 
injected with MCT and randomly assigned into two groups, 
one receiving an anti-TRAIL antibody and the other receiv-
ing an IgG isotype control, for 14 d via a subcutaneous os-
motic mini-pump. Rats treated with IgG developed PAH, 
as defined by elevated right ventricular systolic pressure 
(RVSP), right ventricular end-diastolic pressure (RVEDP), 
reduced pulmonary artery acceleration time (PA AT), increased 
estimated pulmonary vascular resistance index (ePVRi), and 
decreased cardiac index (compared with saline treated rats; 
Table S2), whereas rats that received the anti-TRAIL antibody 
treatment had a normal RVSP (Fig. 3 A), RVEDP (Fig. 3 B), PA 
Figure 2. TRAIL expression in pulmonary arterioles increases with pulmonary vascular remodeling in the MCT rat model. Representative  
photomicrographs of serial lung sections from saline- and MCT-treated rats 14, 21, and 28 d after injection. Sections were stained with Alcian Blue 
Elastic van Gieson (ABEVG) or immunostained for -SMA, von Willebrand factor (vWF), or TRAIL. TRAIL-expressing cells are present within the media 
and perivascular regions of remodeled small pulmonary arteries. All images are representative of n = 7 rats per group at each time point. Bars, 50 µm.
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et al., 2011), we next sought to determine whether TRAIL also 
had a critical role in this model. Using mice that were double 
deficient for ApoE and TRAIL (ApoE//TRAIL/; Watt 
et al., 2011), we examined if TRAIL was similarly required for 
development of PAH.
Consistent with previous data (Lawrie et al., 2011), signifi-
cant increases in RVSP (50.2 ± 3.5 mm Hg; Fig. 5 A) and RVEDP 
(Fig. 5 B), reduced PA AT (Fig. 5 E) and cardiac index (Fig. 5 F), 
TRAIL is required and is sufficient for the development  
of PAH in the Paigen diet-fed ApoE/ mouse model
We have previously reported that ApoE/ mice fed the Paigen 
diet for 8 wk developed severe PAH consisting of substantial 
increases in RVSP associated with obliterative neointimal pul-
monary vascular lesions that share many features with the human 
disease. As this model produced a severe pulmonary vasculop-
athy that was associated with TRAIL immunoreactivity (Lawrie 
Figure 3. Anti-TRAIL antibody treatment prevents the development of PAH at day 21 in the MCT rat model. (A–D) Bar graphs show RVSP  
(A), RVEDP (B), left ventricular end-systolic pressure (LVESP; C), and LVEDP (D), measured in mm Hg. (E–H) PA AT (E), cardiac index (F), ePVRi (G), and RVH 
(H) are shown. (I) The degree of medial wall thickness as a ratio of total vessel size (Media/CSA). (J and K) Quantification of the percentage of proliferating 
cells (PCNA positive; J) and apoptotic (TUNEL positive; K) separated into pulmonary arteries <50 µm in diameter, vessels from 51 to 100 µm in diameter, 
and vessels >100 µm in diameter. (L) Representative photomicrographs of serial lung sections from IgG and anti-TRAIL–treated MCT-induced rats 21 d 
after injection. Sections were stained with Alcian Blue Elastic van Gieson (ABEVG) or immunostained for -SMA, von Willebrand factor (vWF), PCNA, or 
TUNEL. Error bars represent mean ± SEM, n = 4 animals per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001, compared with IgG-treated rats. Arrows point to 
PCNA- or TUNEL-positive cells. Bars, 50 µm.
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remodeling and moderate increase in RVSP there was no signifi-
cant effect of diet on RVH (Fig. 5 H). Severe pulmonary vascular 
remodeling of the small arteries and arterioles comprising SMA-
positive cells was observed in the Paigen diet-fed ApoE/ mice 
compared with their chow-fed littermates (Fig. 5, I and J). In 
contrast, neither the TRAIL/ nor the ApoE//TRAIL/ 
mice fed either chow or Paigen diet demonstrated any evi-
dence of pulmonary vascular remodeling (Fig. 5, I and J).
We next investigated whether adding back recombinant 
TRAIL to the ApoE//TRAIL/ mice would result in any 
alteration of the protected phenotype. ApoE//TRAIL/ 
and increased ePVRi (Fig. 5 G) were observed in ApoE/ mice 
after 8 wk on the Paigen diet. Also as previously reported 
(Lawrie et al., 2011), there was no significant difference in left 
ventricular hemodynamics (Fig. 4, C and D). There was no evi-
dence of PH in either the chow- or Paigen diet–fed TRAIL/ 
mice. Remarkably, ApoE/ mice that were also deficient for 
TRAIL (ApoE//TRAIL/) and fed the Paigen diet were 
protected from developing a significant increase in RVSP 
(27.8 ± 3.2 mm Hg; Fig. 5 A) or other changes in other he-
modynamic markers of PAH (Fig. 5, A–G; Table S4). As with 
our previous data, despite the substantial pulmonary vascular 
Figure 4. TRAIL/ mice are protected from chronic hypoxia–induced PH. (A–D) Bar graphs show (A) RVSP, (B) RVEDP, (C) LVESP, and (D) LVEDP, 
measured in mm Hg. (E–H) PA AT (E), cardiac index (F), ePVRi (G), and RVH (H) are shown. (I) The degree of medial wall thickness as a ratio of total vessel 
size (Media/CSA). (J) The percentage of thickened pulmonary arteries <50 µm in diameter. (K) Representative photomicrographs of serial lung sections from 
C57BL/6 and TRAIL/ mice after 2 wk of exposure to either room air or hypoxia. Sections were stained with Alcian Blue Elastic van Gieson (ABEVG) or im-
munostained for -SMA. Error bars represent mean ± SEM, n = 6–7 animals per group. *, P < 0.05; **, P < 0.01, compared with normoxic mice. Bars, 50 µm.
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similar to those observed in ApoE/ mice fed Paigen diet 
(Fig. 5 A). Although this was not associated with a significant 
increase in RVEDP (Fig. 6 B), there was a trend for reduced 
PA AT (Fig. 6 E) and cardiac index (Fig. 6 F), as well as a sig-
nificant increase ePVRi (Fig. 6 G). As per Fig. 5, there was no 
significant effect on left ventricular hemodynamics (Fig. 6, 
C and D) and no increase in RVH (Fig. 6 H; Table S5). 
mice were randomized into two groups and implanted with os-
motic micro-pumps to deliver either recombinant mouse TRAIL 
or saline as a control for 4 wk. All mice were then placed on the 
Paigen diet for 8 wk. The ApoE//TRAIL/ mice that re-
ceived the recombinant mouse TRAIL demonstrated a signifi-
cantly elevated RVSP (47.5 ± 6.4 mm Hg) compared with those 
receiving saline as control (23.0 ± 1.3 mm Hg; Fig. 6 A) and were 
Figure 5. ApoE//TRAIL/ mice are protected from the development of PAH. (A–D) Bar graphs show RVSP (A), RVEDP (B), LVESP (C), and LVEDP (D), 
measured in mm Hg. (E–H) PA AT (E), cardiac index (F), ePVRi (G), and RVH (H) are shown. (I) The degree of medial wall thickness as a ratio of total 
vessel size (Media/CSA) in pulmonary arteries <50 µm in diameter. (J) Representative photomicrographs of serial lung sections from TRAIL/, ApoE/, 
and ApoE//TRAIL/ mice fed on either regular chow or Paigen diet for 8 wk. Sections were stained with Alcian Blue Elastic van Gieson (ABEVG) or  
immunostained for -SMA or von Willebrand factor (vWF). Error bars represent mean ± SEM, n = 4–7 animals per group. *, P < 0.05; **, P < 0.01;  
***, P < 0.001, compared with chow-fed mice. Bars, 50 µm.
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(Fig. 7, K and M), and although there was no significant effect 
on apoptosis (Fig. 7, L and M), a few apoptotic PASMC were 
observed (Fig. 7 N). Collectively, these data suggest that there 
was a partial slowing of disease progression with the anti-
TRAIL treatment but no evidence of disease reversal. We next 
examined whether we could achieve a greater response and 
induce disease regression using the mouse model. This ap-
proach had to two advantages: (1) use of species-specific anti-
body and (2) implantation of a micro-pump allowing delivery 
of a twofold higher dose (0.8 vs. 0.4 ng/g/h) of the anti-
TRAIL antibody for twice the duration (4 wk).
After 8 wk of feeding on the Paigen diet, ApoE/ mice 
were randomly assigned to two groups and osmotic micro-
pumps were implanted, delivering either anti-TRAIL anti-
body or IgG for 4 wk. Paigen diet–fed ApoE/ mice 
receiving IgG (now 12 wk on diet) displayed a further in-
crease in RVSP compared with the previous study at 8 wk 
(84.7 ± 25.0 vs. 50.2 ± 3.5 mm Hg). During the study, two 
mice, one from each group, were sacrificed early (8–10 wk) 
and failed to make the full 12 wk time course, but their data 
were included in the full analyses so as not to bias any effects 
of the treatment. Mice fed Paigen diet for 12 wk and treated 
with control IgG had severe PAH as demonstrated by dra-
matically increased RVSP (84.7 ± 25.0 mm Hg, Fig. 8 A), 
RVEDP (Fig. 8 B), reduced PA AT (Fig. 8 E), and cardiac 
index (Fig. 8 F) and increased ePVRi (Fig. 8 G). Remark-
ably, mice that received the anti-TRAIL antibody had a 
significant reduction in RVSP (29.5 ± 
3.1 mm Hg) to near normal levels 
(Fig. 8 A). Treatment was also associated 
with a reduction in RVEDP (Fig. 8 B), 
an increase in both PA AT (Fig. 8 E) 
and cardiac index (Fig. 8 F), and a sig-
nificant reduction in ePVRi (Fig. 8 G). 
As previously described, there was no 
effect of the Paigen diet on RVH 
There was also a significant increase in pulmonary vascular re-
modeling comprising SMA-positive cells in the small pulmonary 
arteries and arterioles of mice receiving recombinant mouse 
TRAIL (Fig. 6, I and J) compared with the saline-treated mice.
Treatment of established PAH with an anti-TRAIL antibody 
increases survival and induces reverse remodeling of disease
Our data thus far provided strong evidence that TRAIL was 
necessary for the development of PAH in three independent 
animal models. We next sought to determine whether block-
ing TRAIL with an anti-TRAIL antibody would have any 
beneficial effects on slowing disease progression and, ulti-
mately, if it could induce disease regression. We tested this first 
in the MCT rat model. Rats were injected with MCT and left 
for 21 d before being randomly assigned into two groups re-
ceiving either the anti-TRAIL antibody or IgG control. The 
antibodies were delivered for 14 d using osmotic mini-pumps. 
The rats receiving the anti-TRAIL antibody displayed a signif-
icant increase in survival compared with IgG control animals 
(Fig. 7 A). Although there was no significant change in any of 
the hemodynamic markers of PH or left ventricular hemody-
namics (Fig. 7, B–I; Table S2), there was a nonsignificant in-
crease in cardiac index (Fig. 7 G) and a significant reduction in 
the degree of pulmonary vascular remodeling observed during 
histological analysis within the anti-TRAIL antibody–treated 
animals (Fig. 7, J and M). The reduced media/CSA was asso-
ciated with a significant reduction in vascular proliferation 
Figure 6. Addition of recombinant 
TRAIL to ApoE//TRAIL/ mice reestab-
lished the development of PAH. (A–D) Bar 
graphs show RVSP (A), RVEDP (B), LVESP  
(C), and LVEDP (D), measured in mm Hg.  
(E–H) PA AT (E), cardiac index (F), ePVRi (G), 
and RVH (H). (I) The degree of medial wall 
thickness as a ratio of total vessel size (Media/
CSA) in pulmonary arteries <50 µm in diameter. 
(J) Representative photomicrographs of  
serial lung sections from ApoE//TRAIL/ 
mice fed Paigen diet for 8 wk who received 
either recombinant TRAIL (rTRAIL) or saline 
(placebo) by osmotic micro-pump for 4 wk. 
Sections were stained with Alcian Blue Elastic 
van Gieson (ABEVG) or immunostained for 
-SMA. Error bars represent mean ± SEM,  
n = 4–5 animals per group. *, P < 0.05;  
**, P < 0.01 compared with placebo-treated 
mice. Bars, 50 µm.
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Figure 7. Anti-TRAIL antibody treatment of established PAH in the MCT rat model prolongs survival and reduces pulmonary vascular  
remodeling. (A) Kaplan-Meier plot of survival in IgG and anti-TRAIL–treated rats. (B–E) Bar graphs show RVSP (B), RVEDP (C), LVESP (D), and LVEDP (E), 
measured in mm Hg. (F–I) PA AT (F), cardiac index (G), ePVRi (H), and RVH (I). (J) The degree of medial wall thickness as a ratio of total vessel size  
(Media/CSA). (K and L) Quantification of the percentage of proliferating cells (PCNA positive; K), and apoptotic (TUNEL positive; L) separated into pulmo-
nary arteries <50 µm in diameter, vessels from 51 to 100 µm in diameter, and vessels >100 µm in diameter. (M) Representative photomicrographs of 
serial lung sections from MCT-injected rats treated with either IgG isotype control or an anti-TRAIL antibody. Sections were stained with Alcian Blue Elas-
tic van Gieson (ABEVG) or immunostained for -SMA, PCNA, or TUNEL. (N) Representative confocal microscopy image showing apoptotic cells (green) 
and SMC (red) with dual-positive cells (yellow) highlighted by white arrows. Error bars represent mean ± SEM, n = 6 animals per group. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001 compared with IgG-treated MCT-injected rats. Arrows point to TUNEL-positive cells. Bars, 50 µm.
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Figure 8. Anti-TRAIL antibody treatment of established PAH in the Paigen diet–fed ApoE/ mouse induces disease regression. (A–D) Bar graphs show 
RVSP (A), RVEDP (B), LVESP (C), and LVEDP (D), measured in mm Hg. (E–H) PA AT (E), cardiac index (F), ePVRi (G), and RVH (H). (I) The degree of medial wall thickness 
as a ratio of total vessel size (Media/CSA). (J) Relative percentage of muscularized small pulmonary arteries and arterioles in <50 µm vessels. (K and L) Quantification 
of the percentage of proliferating cells (PCNA positive; K) and apoptotic (TUNEL positive; L) separated into pulmonary arteries <50 µm in diameter, vessels 
JEM Vol. 209, No. 11 
Article
1929
(Fig. 8 H) or left ventricular hemodynamics (Fig. 8, C and D; 
Table S5). The improvement in hemodynamics was associ-
ated with a significant reduction in pulmonary vascular re-
modeling as assessed by medial/CSA (Fig. 8, I and M) and the 
percentage of affected vessels (Fig. 8, J and M). Similar to the 
MCT rat study, there was a significant decrease in the per-
centage of proliferating cell nuclear antigen (PCNA)–positive 
cells in the anti-TRAIL–treated animals (Fig. 8, K and M). 
There was also a significant increase in the number of apoptotic 
cells within remodeled pulmonary arteries (Fig. 8, L and M), 
suggesting that the anti-TRAIL treatment both reduced pro-
liferation and induced apoptosis within the remodeled pulmo-
nary arteries. We further identified that the remaining apoptotic 
cells present within the media of the small pulmonary arteries 
were SMA positive (Fig. 8 N).
Tissue expression of TRAIL drives PAH pathogenesis
Because TRAIL is expressed by both circulating inflammatory 
(e.g., T cells, B cells, neutrophils, and monocytes) and vascular 
cells, which are both implicated in PAH pathogenesis, we next 
determined the relative importance of tissue expression of 
TRAIL compared with circulating BM-derived cells (BMDCs). 
Before performing these experiments, we confirmed the ab-
sence or presence of TRAIL mRNA in ApoE/ or ApoE//
TRAIL/ blood by TaqMan PCR (Fig. 9 A). To perform 
these studies, we generated four groups of chimeric mice by 
BM transplantation (BMT). ApoE/ BM was transplanted 
(BMT) into sublethally irradiated ApoE//TRAIL/ mice 
(ApoE/ into ApoE//TRAIL/) to produce chimeras 
where TRAIL was only expressed within circulating BMDC, 
and into ApoE/ mice as a positive control for the procedure 
(ApoE/ into ApoE/). Conversely, ApoE//TRAIL/ 
BM was transplanted into sublethally irradiated ApoE/ mice 
(ApoE//TRAIL/ into ApoE/) to generate chimeras 
where TRAIL was only expressed within the vessel wall, 
and into ApoE//TRAIL/ (ApoE//TRAIL/ into 
ApoE//TRAIL/) mice as a negative control. 6 wk after 
BM reconstitution, mice were randomly placed on either regu-
lar chow or Paigen diet. The conversion rate of BMT was 
94.9 ± 2.6%. Chow-fed control mice from all BMT groups 
served as a control for the irradiation and transplant procedure 
and displayed no PH phenotype. The presence or absence of 
TRAIL in the recipient lung was confirmed by Western 
immunoblotting (Fig. 8 B). As previously observed, feeding of 
the Paigen diet to the ApoE/ into ApoE/ and ApoE//
TRAIL/ into ApoE//TRAIL/ chimeras recapitulated 
our findings (Fig. 9, C–M) from the nonirradiated Paigen-fed 
ApoE/ and ApoE//TRAIL/ mice (Fig. 5).
The other two groups of chimeric mice with the expression 
of TRAIL limited to either the tissue or circulating BMDCs 
displayed disease symptoms after feeding of the Paigen diet and 
were sacrificed for analysis at 6 wk rather than 8 wk (Fig. 9, C–M). 
Mice with TRAIL on circulating BMDC, but not in tissue 
(ApoE/ into ApoE//TRAIL/), displayed a trend for 
an increase in RVSP (Fig. 9 C), RVEDP (Fig. 9 D), and 
PVRi (Fig. 9 H); however, this did not reach statistical signi-
ficance. Conversely, mice with no TRAIL on circulating 
BMDC but TRAIL within tissue (ApoE//TRAIL/ into 
ApoE/) displayed a significant increase in RVSP (Fig. 9 C), 
RVEDP (Fig. 9 D), ePVRi (Fig. 9 H), and a significant reduc-
tion in cardiac index (Fig. 9 G) that was equivalent to the 
ApoE/ into ApoE/ mice (Table S6). Histological analysis 
and quantification revealed that the reduced RVSP in the 
ApoE/ into ApoE//TRAIL/ chimeras was the result of 
a reduction in pulmonary artery and arteriole remodeling, both 
in terms of the number of vessels affected and the degree of 
muscularization within those affected vessels (Fig. 9, J–M). 
During these analyses, we observed that some lungs displayed 
signs of alveolar septa thickening and mild fibrosis, and subse-
quently applied the modified Ashcroft scoring (Hübner et al., 
2008) to all lung sections. Although only mild changes were 
observed (maximum of 2 from an 8-point scale), interestingly, 
mice with only TRAIL on circulating cells (ApoE/ into 
ApoE//TRAIL/) had no fibrosis and all scored 0 on the 
modified Ashcroft score (unpublished data).
These data demonstrate that lung tissue expression of 
TRAIL is the predominate driver of the pulmonary vascular 
remodeling and the subsequent increase in RVSP that is con-
sistent with the development of PAH in this model, although 
a role for TRAIL expressed on circulating BMDC cannot be 
completely dismissed.
DISCUSSION
In this study, we report for the first time that TRAIL expression 
is up-regulated in PASMCs isolated from patients with IPAH, 
and TRAIL is a mitogen and promigratory stimulus for human 
PASMCs in vitro. Furthermore, we demonstrate through the 
blockade of TRAIL via either genetic deletion (mice) or with 
an anti-TRAIL antibody (MCT-treated rat) that TRAIL is re-
quired for the development of PAH in three rodent models. 
Moreover, we have demonstrated the ability of anti-TRAIL 
antibody treatment to reduce proliferation and increase apopto-
sis, thereby inducing regression of established pulmonary arte-
rial remodeling and reducing right ventricular pressures.
The number of pharmacological interventions for the treat-
ment of PAH has increased dramatically over the last decade. 
However, these therapies are restricted principally to targeting 
three main signaling pathways associated with vasoconstriction, 
namely endothelin-1, nitric oxide, and prostacyclin (Humbert 
et al., 2004). Pulmonary vascular vasoconstriction is only one of 
from 51 to 100 µm in diameter, and vessels >100 µm in diameter. (M) Representative photomicrographs of serial lung sections from ApoE/ mice fed on Paigen 
diet for 12 wk. Sections were stained with Alcian Blue Elastic van Gieson (ABEVG) or immunostained for -SMA, PCNA, or TUNEL. (N) Representative confocal mi-
croscopy image showing apoptotic cells (green) and SMC (red) with dual-positive cells (yellow) highlighted by white arrows. Error bars represent mean ± 
SEM, n = 4–6 animals per group. *, P < 0.05; **, P < 0.01, compared with IgG-treated Paigen diet-fed mice. Arrows point to TUNEL-positive cells. Bars, 50 µm.
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is clear that despite these new therapeu-
tic approaches there is a need for iden-
tification of new specific targets and 
therapies to reverse this debilitating and 
fatal disease.
The dogma from early studies in on-
cology describes TRAIL as a death li-
gand that can selectively induce apoptosis 
of transformed tumor cells (Wiley et al., 
1995; Pitti et al., 1996). After initial opti-
mism that TRAIL may represent a new 
therapy for cancer, it is apparent that several cancer cell types 
have acquired resistance to TRAIL-induced apoptosis in vivo 
(Wu, 2009). Current strategies now focus on resensitizing 
tumor cells to the effects of TRAIL with the use of combina-
tion therapy.
Since its discovery, several additional roles for TRAIL have 
been described, particularly in the context of immunoregula-
tory functions and immune surveillance (Falschlehner et al., 
2009; Ikeda et al., 2010). Of particular relevance to our own 
the pathophysiological drivers for PAH and, although postu-
lated, there is little proof that any of these drugs have any direct 
effect on pulmonary vascular proliferation or have the capacity 
to reverse the proliferative changes in PAH (Schermuly et al., 
2005). Although several new targets and drugs have been 
proposed (Ghofrani et al., 2009), e.g., the inhibition of growth 
factors such as PDGF that can target the vascular proliferation 
(Schermuly et al., 2005; Ghofrani et al., 2010), most are gener-
ally not specific to the pulmonary circulation. Subsequently, it 
Figure 9. TRAIL expression within the 
pulmonary vascular tissue drives PAH in 
the Paigen diet–fed ApoE/ mouse.  
(A) TaqMan expression of TRAIL in whole 
blood from ApoE/ and ApoE//TRAIL/ 
mice using CT with 18S rRNA as the  
endogenous control gene. Four groups of chi-
meric mice were generated by BMT. ApoE/ 
BM was transplanted into irradiated 
ApoE//TRAIL/ mice (ApoE/ into 
ApoE//TRAIL/) to produce chimeras 
where TRAIL was only expressed within cir-
culating cells, and into ApoE/ mice as a 
positive control for the procedure (ApoE/ into 
ApoE/). Conversely, ApoE//TRAIL/ BM 
was transplanted into irradiated ApoE/ 
mice (ApoE//TRAIL/ into ApoE/) to 
generate chimeras where TRAIL was only 
expressed within the vessel wall, and into 
ApoE//TRAIL/ (ApoE//TRAIL/ into 
ApoE//TRAIL/) mice as a negative con-
trol. (B) Western immunoblot for TRAIL in 
whole lung lysates from representative chi-
meric mice. (C–F) Bar graphs show RVSP  
(C), RVEDP (D), LVESP (E), and LVEDP  
(F), measured in mm Hg. (G–I) Cardiac index 
(G), ePVRi (H), and RVH (I). (J) Relative per-
centage of muscularized small pulmonary 
arteries pulmonary arteries <50 µm in diam-
eter, and the degree of medial wall thickness 
as a ratio of total vessel size (Media/CSA). 
(K–M) Pulmonary arteries <50 µm in diam-
eter (K), vessels from 51 to 100 µm in diam-
eter (L), and vessels >100 µm in diameter 
(M). Error bars represent mean ± SEM,  
n = 3–6 animals per group. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001, compared chow-fed 
equivalent mice unless otherwise stated.
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calpain may play an important role in allowing paracrine 
effects of cleaved soluble TRAIL on multiple cells types. 
This may also explain why the systemic delivery of recom-
binant soluble form of TRAIL, without direct presentation 
by another cell, to Paigen diet–fed ApoE//TRAIL/ 
mice resulted in the development of a PAH phenotype 
suggesting that soluble/cleaved levels within the vessel wall 
are critically important.
Our current study was limited by access to species-specific 
polyclonal antibodies, so for both intervention studies an anti–
mouse TRAIL polyclonal was used. One limitation of the rat 
studies was that the dose of antibody administered to block the 
development of PAH in the MCT rat was limited and conse-
quently this may explain the only modest effect on reversal of 
established disease whether this may have been increased if a 
higher does of antibody could have been given is not known. 
To address this concept in the mouse (as reagents were avail-
able), we subsequently performed a second reversal study in 
the mouse with twice the concentration of antibody for twice 
the duration of treatment. This resulted in normalization of 
RVSP, significantly reduced pulmonary artery remodeling, 
and an almost complete reversal in PAH phenotype.
Although there are several limitations of each individual 
model used, particularly in regard to the mouse, we believe that 
the combination of three rodent experimental models, each with 
different disease triggers, add substantial weight to the body of 
evidence that TRAIL is a key driver in the pulmonary vascular 
remodeling associated with PAH. We are currently exploring the 
future therapeutic potential for anti-TRAIL–based therapies.
MATERIALS AND METHODS
PASMC RNA from patients with IPAH. Explanted PASMCs grown in 
culture from proximal lobar and peripheral arteries (1–2 mm external diameter) 
from patients with IPAH (n = 3) and control (n = 3). Smooth muscle phenotype 
of isolated cells was confirmed by positive immunofluorescence with antibodies 
to -SMA, smooth muscle–specific myosin, fibronectin, and vimentin as previ-
ously described (Yang et al., 2005). RNA was extracted by TRIzol (Invitrogen). 
Clinical data on donor is provided in Table S1. All subjects gave informed written 
consent, and the study was approved by the Local Research Ethics Committee 
and Papworth Hospital NHS Trust tissue bank, Cambridge, UK.
TaqMan PCR. RNA was reverse transcribed using Superscript III (Invitrogen). 
Gene expression was measured by performing TaqMan PCR using Gene 
Expression MasterMix and Gene Expression Assays (Applied Biosystems) 
for TRAIL (Hs00234356_m1), TRAIL-R1 (Hs00269492_m1), TRAIL-R2 
(Hs00366278_m1), TRAIL-R3 (Hs00182570_m1), and TRAIL-R4 
(Hs04187520_m1). Gene expression was normalized to 18S rRNA (999999011) 
using the CT comparative quantification method as previously described 
(Lawrie et al., 2005).
Cell culture and phenotypic assays. Human PA-SMCs (Cascade Biolog-
ics) were maintained as previously described (Lawrie et al., 2008). Before 
stimulation, PA-SMCs were synchronized by incubating in DME medium 
containing PSA Solution (Invitrogen) and 0.2% (vol/vol) fetal bovine serum 
(Invitrogen) for 48 h. Cell proliferation was assessed using Coulter counting, 
and migration using a Boyden chamber assay as previously described (Leung 
et al., 2004). Where stated, cells were stimulated with recombinant human 
TRAIL or PDGF (both R&D Systems)
Animals. Male Sprague Dawley rats were purchased from Charles River. 
PAH was induced in rats 200–210 g by a single subcutaneous injection of MCT 
studies has been an emerging body of work supporting an im-
portant role for TRAIL in vascular biology, both in the context 
of interactions between inflammation and vascular cells and via 
direct effects on VSMC proliferation and migration (Secchiero 
et al., 2004; Kavurma et al., 2008; Chan et al., 2010). Endothe-
lial cells have also been shown to express TRAIL and its recep-
tors (Pan et al., 1997b; Secchiero et al., 2003), and the role of 
TRAIL on endothelial cell survival is debated (Gochuico et al., 
2000; Malyankar et al., 2000; Li et al., 2003; Secchiero et al., 
2003; Zauli and Secchiero, 2006). Interestingly, additional stud-
ies have also highlighted a role for TRAIL in the migration of 
BM stem cells (Secchiero et al., 2008) which have been postu-
lated to contribute to vascular remodeling.
In the context of PAH, there is evidence in the literature 
that TRAIL expression may be regulated by several pathways 
associated with PAH, including bone morphogenetic proteins 
(Nguyen et al., 2007), fibroblast growth factor 2 (FGF2; Chan 
et al., 2010), and early growth response factor 1 (EGR1; Droin 
et al., 2003; Fu et al., 2003), all of which are implicated in driv-
ing the pathogenesis of PAH (Benisty et al., 2004; Izikki et al., 
2009; Morrell et al., 2009; Dickinson et al., 2011; Tu et al., 
2011). Interestingly, EGR1 has also been shown to regulate 
survivin (Wagner et al., 2008) and RAGE (Xu et al., 2010), 
both of which have been suggested as potential targets for the 
treatment of PAH (Lawrie et al., 2005; McMurtry et al., 2005; 
Spiekerkoetter et al., 2009). There is also evidence that peroxi-
some proliferator-activated receptor  (PPAR) activation via 
agonists rosiglitazone or troglitazone can decrease the expres-
sion TRAIL mRNA (Fionda et al., 2007). PPAR has gained 
significant recent interest in the context of PAH (Rabinovitch, 
2010) and may be particularly pertinent to the mouse model 
used in this study. Rosiglitazone has been shown to reverse 
PAH in the ApoE/ mouse fed a western diet (Hansmann 
et al., 2007), as well as the hypoxic mouse model (Nisbet et al., 
2010). Furthermore, the genetic deletion of PPAR in either 
SMCs (Hansmann et al., 2008) or endothelial cells (Guignabert 
et al., 2009) results in a PAH phenotype in mice by a mechanism 
involving PDGF and BMP signaling. Conversely, it has been 
reported that PPAR can activate membrane TRAIL expres-
sion in macrophages (Ho et al., 2011). Similarly, in cancer cells 
it has been shown that PPAR agonists can up-regulate the 
expression of TRAIL receptors and enhance sensitivity to 
TRAIL-induced apoptosis (Lu et al., 2005; Zou et al., 2007; 
Bräutigam et al., 2011), suggesting that PPAR regulation of 
TRAIL may be tissue and cell specific.
In our current study, data from TRAIL chimeric mice 
suggest that TRAIL expression by cells in the vessel wall 
is the main driver in the pathological process. TRAIL is 
a membrane-anchored protein that can be enzymatically 
cleaved by cysteine proteases to generate a soluble form of 
TRAIL (Mariani and Krammer, 1998). Cysteine proteases, 
including caspases, calpain, and papain, are abundant within 
the vessel wall (Chapman et al., 1997). Calpain in particu-
lar has recently been shown to be important in pulmonary 
vascular remodeling in animal models of PAH (Ma et al., 
2011). Cleavage of TRAIL by cysteine proteinases such as 
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RVH. RVH was measured by calculating the ratio of the right ventricular 
free wall over left ventricle plus septum.
Immunohistochemistry. Immediately after harvest, the left lung was 
perfusion fixed via the trachea with 10% (vol/vol) formal buffered saline by 
inflation to 20 cm of H2O. The lungs were then processed into paraffin 
blocks for sectioning. Paraffin-embedded sections (5 µm) of lung were his-
tologically stained for Alcian Blue Elastin van Gieson (ABEVG), immuno-
histochemically stained for -SMA (M0851; Dako) to visualize SMCs and 
von Willebrand Factor (vWF; A0082; Dako) to visualize endothelial cells, 
and TRAIL (ab2435; Abcam) was also used to localize protein expression to 
pulmonary vascular lesions. To assess proliferation, slides were stained with 
a mouse anti–human PCNA antibody (M0879; Dako). A secondary bioti-
nylated anti–mouse antibody (1:200) was added before an Avidin Biotin 
enzyme Complex (Vectastain kit; Vector Laboratories). All protocols used 
3,3 diaminobenzidine as the substrate for color in the peroxidase reaction 
and counterstained with hematoxylin.
Apoptotic nuclei were detected with a TdT-mediated dUTP nick-end 
labeling (TUNEL) assay using a colorimetric DNA fragmentation detection 
kit (fragEL; QIA33; EMD Millipore; Merck) according to the manufacturer’s 
instruction and counterstained with methyl green. To further define apoptotic 
cells, we used the Fluorescein in situ Cell Death Detection kit (Roche) with 
Alexa Fluor 555 secondary antibody to detect -SMA (M0851). Images were 
captured on an inverted confocal and multiphoton microscope (LSM 510 
NLO; Carl Zeiss). For both the Fluorescein and Alexa Fluor 555, we used an 
HFT488/543/633 dichroic mirror with an NFT545 beam splitter and a 
488 nm Argon laser for Fluorescein with a 500–530 band pass filter, a 543 
HeNe for Alexa Fluor 555 with a 565–615 nm band pass filter, a Coherent 
Chameleon laser tuned to 740 nm for multiphoton excitation, a KP650 dichroic 
mirror, a BG39 IR filter, and a spectral detector set to collect 394–480 nm light 
for the detection of DAPI. The specimens were scanned using each laser/fluor-
escence channel sequentially to reduce the risk of fluorescence artifacts.
Quantification of pulmonary vascular remodeling. Pulmonary vascular 
remodeling was quantified by assessing the degree of muscularization and the 
percentage of affected pulmonary arteries and arterioles in three groups based 
on vessel size: small pulmonary arterioles with a diameter <50 µm, medium 
pulmonary arteries with a range in diameter from 51 to 100 µm, and large pul-
monary arteries with a diameter >100 µm, and standard immunohistochemical 
techniques were applied as previously described (Lawrie et al., 2011). In all 
cases, both IgG and no primary antibody negative controls were used.
Western immunoblotting. 20 µg of each sample was loaded on a 4–12% 
Bis-Tris NuPage gel and run under reducing conditions in MES running buffer 
(Invitrogen) before transfer to a nitrocellulose membrane (Invitrogen). Trans-
fer was confirmed with Ponceau S (Sigma-Aldrich) staining and the membrane 
was then blocked for 1 h in 5% nonfat milk at room temperature. The blots 
were incubated with either phospho-p44/42 MAPK (Erk1/2; Thr202/Tyr204) 
rabbit monoclonal antibody (Cell Signaling Technology), p44/42 MAPK 
(Erk1/2) mouse monoclonal antibody (Cell Signaling Technology), or 
anti–b-Actin mouse monoclonal antibody (Abcam) for 1 h at room tempera-
ture, or anti-TRAIL rabbit polyclonal antibody (Abcam) overnight at 4°C. For 
detection of p44/42, horseradish peroxidase (HRP)–conjugated anti–mouse 
and anti–rabbit antibodies (1:5000; GE Healthcare) were incubated for 1 h at 
room temperature before performing an enhanced chemiluminescence (ECL; 
GE Healthcare) reaction and exposure to autoradiographic film (GE Health-
care). For detection of TRAIL and b-Actin, fluorescently labeled anti–rabbit 
(IR Dye 800CW; LI-COR Biosciences) and anti–mouse (IRDye 680RD) 
were incubated for 1 h at room temperature before reading at 700/800 nm on 
an Odyssey SA imaging system (LI-COR Biosciences).
Statistical analyses. Statistical analysis was performed using either a Mann-
Whitney test when comparing two groups, or a Kruskal-Wallis followed by 
the Dunns post-hoc test with a 95% confidence level. P < 0.05 was deemed 
statistically significant (Prism 4.0c for Macintosh; GraphPad Software).
(Sigma-Aldrich) at 60 mg/kg. All mice were on a C57BL/6 background. 
TRAIL/ mice were originally developed by Amgen/Immunex, obtained as 
previously described (Watt et al., 2011; Cretney et al., 2002), and obtained by 
material transfer agreement from Amgen Inc. For the chronic hypoxia model, 
male TRAIL/ mice aged 12–13 wk of age (six to eight per group) were placed 
in hypoxic chambers (10% oxygen) for 2 wk to induce PH. (ApoE/ (JAX 
2052) were obtained from The Jackson Laboratory, and ApoE//TRAIL/ 
mice were generated in house as previously described (Watt et al., 2011). All 
mice used were from colonies with greater than six backcrosses. In all experi-
ments, chow-fed, IgG-, or Saline-treated littermate rodents were used as ex-
perimental controls. Male mice, 10–12 wk of age (four to seven per group), 
were fed normal chow (4.3% fat, 0.02% cholesterol, 0.28% sodium) or Paigen 
diet (18.5% fat, 0.9% cholesterol, 0.5% cholate, and 0.259% sodium) for 8 wk 
as previously described (Lawrie et al., 2011). Where stated, recombinant mouse 
TRAIL (rmTRAIL; PeproTech), polyclonal goat anti–mouse TRAIL (anti-
TRAIL), or control goat IgG isotype antibodies (R&D Systems) were delivered 
to rodents through subcutaneously implanted osmotic pumps (Durect Corp.). 
Interventions were delivered via an Alzet 1004 micro pump (100 µl reservoir, 
0.1 µl/h for 4 wk) in mice and via an Alzet 2002 mini-pump (200 µl reservoir, 
0.5 µl/h for 2 wk) in rats. Antibodies were delivered at 84 ng/h (0.4 ng/g/h) 
in rats and 20 ng/h (0.8 ng/g/h) in mice; rmTRAIL was administered at 
10 ng/h (0.4 ng/g/h). For the rat survival studies animals, right heart failure 
(RHF) served as the survival end point. RHF was defined by loss of body 
weight (either >5%/24 h or >10%/48 h), lethargy, and respiratory distress as 
previously described (Merklinger et al., 2005; de Man et al., 2012). All animal 
experiments were approved by the University of Sheffield Project Review 
Committee and conformed to UK Home Office ethical guidelines.
BMT. BMT was performed as previously described (Chamberlain et al., 
2006). In brief, male mice, 6–8 wk old, received a sublethal dose of whole-
body irradiation (1,100 rads, split into two doses, 4 h apart). Irradiated recipi-
ents then received three to four million cells, isolated from 4–6-wk-old mice 
in Hanks’ balanced salt solution, by tail-vein injection. After 6 wks of recov-
ery on regular chow, mice were randomly assigned to chow or Paigen diets 
for a further 8 wk as described in the Animals section.
Echocardiography. Echocardiography was performed using the Vevo 770 
system (Visual Sonics) using either the RMV707B (mice) or RMV710B (rat) 
scan head. Rodents were placed on a heated platform and covered to minimize 
heat loss. Rectal temperature, heart rate and respiratory rate were recorded 
continuously throughout the study. Anesthesia was induced and maintained 
using Isoflurane through oxygen maintaining heart rates at 450–500 (mice) 
and 325–350 (rats) beats per minute (bpm), whenever possible. The rodents 
were depilated and preheated ultrasound gel was applied (Aquasonics 100 Gel; 
Parker Laboratories Inc.), and echocardiography was performed and analyzed 
as previously described (Lawrie et al., 2011) with PA AT reported as data sup-
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